Join
Live feed
·
PRReleasevia Quantisnow
Belite Bio Inc logo

Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1

ByQuantisnow·Wall Street's wire, on your screen.
BLTE· Belite Bio Inc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BLTE (Belite Bio Inc) and more on Quantisnow.